Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
1.530
-0.020 (-1.29%)
At close: Jan 2, 2026, 4:00 PM EST
1.480
-0.050 (-3.27%)
After-hours: Jan 2, 2026, 4:47 PM EST
Equillium Employees
Equillium had 35 employees as of December 31, 2024. The number of employees decreased by 9 or -20.45% compared to the previous year.
Employees
35
Change (1Y)
-9
Growth (1Y)
-20.45%
Revenue / Employee
$125,486
Profits / Employee
-$697,629
Market Cap
93.17M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35 | -9 | -20.45% |
| Dec 31, 2023 | 44 | 8 | 22.22% |
| Dec 31, 2022 | 36 | -9 | -20.00% |
| Dec 31, 2021 | 45 | 14 | 45.16% |
| Dec 31, 2020 | 31 | 15 | 93.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EQ News
- 6 weeks ago - Equillium to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update - GlobeNewsWire
- 2 months ago - Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript - Seeking Alpha
- 2 months ago - Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 - GlobeNewsWire
- 3 months ago - Equillium Announces Leadership and Corporate Updates - GlobeNewsWire
- 3 months ago - NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor - GlobeNewsWire
- 4 months ago - Equillium to Participate in the Cantor Global Healthcare Conference 2025 - Business Wire